Targeting epidermal growth factor receptor-related signaling pathways in pancreatic cancer

Pancreas

Volumn 44, Issue 7, 2015, Pages 1046-1052

  Philip, Philip A ^a   Lutz, Manfred P ^b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b KLINIKUM SAARBRÜCKEN   (Germany)

Author keywords

Biomarkers; epidermal growth factor receptor; erlotinib; molecular targeted therapy; pancreatic cancer

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MOLECULAR THERAPY AGENT; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; ERLOTINIB; PROTEIN KINASE INHIBITOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; ONCOGENE K RAS; PANCREAS CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PROCEDURES; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ERLOTINIB HYDROCHLORIDE; HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84942022112     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000389     Document Type: Review

References (0)